IP Library Granted Patent US 8,168,622
Granted Patent B2
US 8,168,622 · App. 12/785,388 · Granted May 1, 2012

β-lactamase-resistant cephalosporin ester compounds and salts of thereof

Assignee: Zhejiang Yongning Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,168,622
App. No.
12/785,388
Granted
May 1, 2012
Kind
B2
Abstract

β-lactamase resistant cephalosporin ester compound chosen from those represented by formula (I): wherein, and pharmaceutical salts thereof, composition thereof, and use thereof are disclosed.

Claims (31)

1. A β-lactamase resistant cephalosporin ester compound chosen from those represented by formula (I):

wherein,

and pharmaceutical salts thereof.

2. A β-lactamase resistant cephalosporin ester compound of claim 1 chosen from the pharmaceutical salts.

3. A β-lactamase resistant-cephalosporin ester compound of claim 1 chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are inorganic salts.

4. A β-lactamase resistant cephalosporin ester compound of claim 1 chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are organic salts.

5. A β-lactamase resistant cephalosporin ester compound of claim 1 chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are chosen from hydrochlorides, sulphates, p-toluenesulfonates, tartrates, maleates, and lactates.

6. A β-lactamase resistant cephalosporin ester compound of claim 1 chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are chosen from hydrochlorides and sulphates.

7. A β-lactamase resistant cephalosporin ester compound of claim 1 chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are chosen from p-toluenesulfonates, tartrates, maleates, and lactates.

8. A composition, comprising:

a β-lactamase resistant cephalosporin ester compound; and

a physiologically acceptable carrier, and

wherein the β-lactamase resistant cephalosporin ester compound is chosen from those represented by formula (I):

wherein,

and pharmaceutical salts thereof.

9. A composition of claim 8 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts.

10. A composition of claim 8 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are inorganic salts.

11. A composition of claim 8 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are organic salts.

12. A composition of claim 8 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are chosen from hydrochlorides, sulphates, p-toluenesulfonates, tartrates, maleates, and lactates.

13. A composition of claim 8 , comprising an incipient suitable for oral administration.

14. A method of treating an infection, comprising:

orally administering to a patient in need of the treatment an effective amount of a β-lactamase resistant cephalosporin ester compound as an effective ingredient,

wherein the β-lactamase resistant cephalosporin ester compound is chosen from those represented by formula (I):

wherein,

and pharmaceutical salts thereof.

15. A method of claim 14 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts.

16. A method of claim 14 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are inorganic salts.

17. A method of claim 14 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are organic salts.

18. A method of claim 14 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are chosen from hydrochlorides, sulphates, p-toluenesulfonates, tartrates, maleates, and lactates.

19. A method of claim 14 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are chosen from hydrochlorides and sulphates.

20. A method of claim 14 , wherein the β-lactamase resistant cephalosporin ester compound is chosen from the pharmaceutical salts, and wherein the pharmaceutical salts are chosen from p-toluenesulfonates, tartrates, maleates, and lactates.

Assignments (1)
CHANGE OF NAME Recorded Feb 23, 2012
From: ZHEJIANG YONGNING PHARMACEUTICAL FACTORY
To: ZHEJIANG YONGNING PHARMACEUTICAL CO., LTD.
Reel/Frame 027749/0245 →
Priority Claims (2)
CN 2003 1 0108979 · Nov 28, 2003 · national
CN 2004 1 0083434 · Sep 29, 2004 · national
Continuity (2)
Continuation 10580561
Related Publication 20100227843A1 · Sep 9, 2010